Melanoma and the Microbiome: Exploring the Connection and its Impact on Treatment

Hailee Breanna^*
*Correspondence: Hailee Breanna, Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA, Email:

Keywords

Therapeutic approaches • Disease • Melanoma • Microorganisms • Melanocytes

Introduction

Melanoma is a complex disease characterized by uncontrolled growth of melanocytes, the cells responsible for pigment production in the skin. Its incidence has been rising globally and while early-stage melanoma has a high cure rate, metastatic melanoma is notoriously difficult to treat. Traditional treatments include surgery, chemotherapy, radiation and targeted therapies. Recently, immunotherapy has shown promise, particularly with checkpoint inhibitors like pembrolizumab and nivolumab.

The microbiome, encompassing the trillions of microorganisms residing in the human body, plays a crucial role in various physiological processes, including immune modulation, metabolism and even cancer progression. Recent studies suggest that the microbiome may influence melanoma development, progression and response to treatment, offering new avenues for research and therapy.

Literature Review

The microbiome and melanoma development

Microbiome composition and skin cancer risk: The skin microbiome consists of bacteria, fungi, viruses and other microorganisms that maintain skin homeostasis. Disruptions in this microbial community known as dysbiosis can lead to inflammatory skin conditions and may contribute to skin cancer risk.

Research has shown that certain bacterial species are associated with inflammatory skin diseases like psoriasis and atopic dermatitis, which can increase melanoma risk. For instance, an imbalance in the skin microbiome, with overgrowth of pathogenic bacteria and depletion of beneficial ones, could create an inflammatory environment conducive to tumor development [1,2].

Microbial influence on immune response: The microbiome affects systemic immunity and may influence melanoma development. Gut microbiota, in particular, plays a role in modulating the systemic immune system through the production of metabolites and the activation of immune cells. For example, Short-Chain Fatty Acids (SCFAs) produced by gut bacteria have been shown to influence T cell function and inflammatory responses.

In melanoma, an altered microbiome could impact the efficacy of immune checkpoint inhibitors. Studies have reported correlations between specific gut microbiota compositions and improved responses to immunotherapy. This suggests that the microbiome may affect the host's immune landscape, influencing melanoma progression and treatment outcomes [3].

The microbiome and melanoma treatment

Microbiome as a predictive biomarker: Given the microbiome's potential impact on immune responses, it could serve as a biomarker for predicting melanoma treatment outcomes. Analyzing microbiome composition in patients undergoing treatment could provide insights into their likely response to therapies such as immunotherapy.

For instance, a study found that melanoma patients with a diverse gut microbiome had better responses to immune checkpoint inhibitors compared to those with less diverse microbiomes. This suggests that microbial diversity might be an indicator of a more robust immune system capable of responding more effectively to treatment [4].

Microbiome-based therapeutic strategies: The potential for microbiome-based therapies is also being explored. Probiotic and prebiotic interventions aim to restore a healthy microbiome balance and enhance immune responses against melanoma. Early studies suggest that specific probiotics might improve the efficacy of immunotherapy by modulating the gut microbiota and enhancing systemic immune responses.

Additionally, Fecal Microbiota Transplantation (FMT), a procedure that involves transferring microbiota from a healthy donor to a patient, is being investigated as a strategy to alter the microbiome and improve treatment outcomes. While still experimental, FMT shows promise in enhancing responses to immunotherapy by rebalancing the gut microbiota [5,6].

Discussion

Despite promising findings, several challenges remain in understanding and utilizing the microbiome's role in melanoma treatment. The complexity of the microbiome, with its vast diversity and variability between individuals, makes it difficult to pinpoint specific microbial signatures or mechanisms. Additionally, the interactions between the microbiome and the host immune system are intricate and not yet fully understood.

Future research should focus on longitudinal studies to track changes in the microbiome over time and their impact on melanoma progression and treatment response. Large-scale clinical trials are needed to validate microbiome-based biomarkers and therapeutic interventions. Advances in sequencing technologies and bioinformatics will also be crucial in deciphering the microbiome's role in melanoma.

Conclusion

The connection between melanoma and the microbiome is an exciting and evolving field of research. While still in its early stages, the evidence suggests that the microbiome may influence melanoma development, progression and treatment outcomes. By further exploring this relationship, researchers hope to identify novel biomarkers and therapeutic strategies that could improve melanoma management and patient outcomes.

As our understanding of the microbiome's role in melanoma deepens, it may pave the way for innovative treatments that harness the power of microbial communities to fight cancer. Continued research in this area holds the promise of transforming melanoma care and enhancing our ability to combat this challenging disease.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Maronese, Carlo Alberto, Matthew A. Pimentel, May M. Li and Giovanni Genovese, et al. "Pyoderma gangrenosum: An updated literature review on established and emerging pharmacological treatments." Am J Clin Dermatol 23 (2022): 615-634.

Google Scholar, Crossref, Indexed at

2. Sterne, Jonathan AC, Jelena Savović, Matthew J. Page and Roy G. Elbers, et al. "RoB 2: A revised tool for assessing risk of bias in randomised trials." BMJ 366 (2019).

Google Scholar, Crossref, Indexed at

3. Vilcek, J., V.J. Palombella, D.O.R.O.T.H.Y. Henriksen-DeStefano and C.H.R.I.S.T.I.N.A. Swenson, et al. "Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors." J Exp Med 163 (1986): 632-643.

Google Scholar, Crossref, Indexed at

4. Polunovsky, Vitaly A., Christine H. Wendt, David H. Ingbar and Mark S. Peterson, et al. "Induction of endothelial cell apoptosis by TNFα: Modulation by inhibitors of protein synthesis." Exp Cell Res 214 (1994): 584-594.

Google Scholar, Crossref, Indexed at

5. Detmar, M and C.E. Orfanos. "Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro." Arch Dermatol Res 282 (1990): 238-245. 

Google Scholar, Crossref, Indexed at

6. Trengove, Naomi J., Michael C. Stacey, Shawn Macauley and Neil Bennett, et al. "Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors." Wound Repair Regen 7 (1999): 442-452.

Google Scholar, Crossref, Indexed at